Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

2.750 -0.010 (-0.36%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Diamedica Therapeutics Inc

< Previous 1 2 3 4 Next >
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Preview: DiaMedica Therapeutics
 
Via Benzinga
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics's Earnings Outlook
 
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics: Q2 Earnings Insights
  DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
DiaMedica Therapeutics Earnings Preview
  DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
Via Benzinga
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
3 Penny Stocks Insiders Are Buying: DiaMedica Therapeutics, Troika Media And More
U.S. stock futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 49 companies set new 52-week lows. 
Via Benzinga
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.